

Roger Levy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/666710/publications.pdf>

Version: 2024-02-01

105
papers

7,476
citations

117625

34
h-index

54911

84
g-index

114
all docs

114
docs citations

114
times ranked

6085
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2022, 74, 324-335.	3.4	39
2	Evaluation of endothelial function in patients with Behçet's disease in remission: A cross-sectional study. , 2022, 9, 139-143.		4
3	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. <i>Lupus Science and Medicine</i> , 2022, 9, e000634.	2.7	18
4	Identifying Barriers to Enrollment in Patient Pregnancy Registries: Building Evidence Through Crowdsourcing. <i>JMIR Formative Research</i> , 2022, 6, e30573.	1.4	0
5	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.	3.4	60
6	Soluble Flt-1, Placental Growth Factor, and Vascular Endothelial Growth Factor Serum Levels to Differentiate Between Active Lupus Nephritis During Pregnancy and Preeclampsia. <i>Arthritis Care and Research</i> , 2021, 73, 717-721.	3.4	12
7	Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e122-e130.	3.9	21
8	16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2021, 30, 1314-1326.	1.6	9
9	Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up. <i>BMC Pulmonary Medicine</i> , 2021, 21, 251.	2.0	4
10	10 Years of belimumab experience: What have we learnt?. <i>Lupus</i> , 2021, 30, 1705-1721.	1.6	53
11	The SLICC/ACR Damage Index (SDI) may predict adverse obstetric events in patients with systemic lupus erythematosus. <i>Lupus</i> , 2021, 30, 1966-1972.	1.6	0
12	Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. <i>Rheumatology</i> , 2020, 59, 281-291.	1.9	55
13	Epidemiologic Features of Systemic Vasculitides in the Southeast Region of Brazil. <i>Journal of Clinical Rheumatology</i> , 2020, 26, S106-S110.	0.9	9
14	Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature. <i>Lupus</i> , 2020, 29, 1528-1543.	1.6	14
15	The role of baseline BlyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis. <i>Arthritis Research and Therapy</i> , 2020, 22, 102.	3.5	23
16	Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. <i>Lupus</i> , 2020, 29, 1011-1020.	1.6	79
17	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36.	1.7	13
18	Use of synthetic and biologic DMARDs during pregnancy. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 27-39.	3.0	7

#	ARTICLE	IF	CITATIONS
19	The interplay between tuberculosis and systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2018, 30, 395-402.	4.3	35
20	New and upcoming treatments in antiphospholipid syndrome: A comprehensive review. <i>Pharmacological Research</i> , 2018, 133, 108-120.	7.1	7
21	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Tj ETQq1 1 0.784314 rgBT/Overload Diseases. 2018, 77, 1549-1557.	0.9	96
22	Computed tomography trachea volumetry in patients with scleroderma: Association with clinical and functional findings. <i>PLoS ONE</i> , 2018, 13, e0200754.	2.5	2
23	Challenging cases in rheumatic pregnancies. <i>Rheumatology</i> , 2018, 57, v18-v25.	1.9	5
24	Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2018, 17, 755-767.	5.8	18
25	<scp>CCL</scp>2, <scp>CXCL</scp>8, <scp>CXCL</scp>9 and <scp>CXCL</scp>10 serum levels increase with age but are not altered by treatment with hydroxychloroquine in patients with osteoarthritis of the knees. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1958-1964.	1.9	22
26	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
27	History, Classification, and Subsets of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 1-16.	0.1	3
28	Ocular involvement in patients with spondyloarthritis. <i>Rheumatology</i> , 2017, 56, 2060-2067.	1.9	26
29	Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 484-496.	0.7	11
30	Rapidly progressive diffuse systemic sclerosis after local vitamins A, D and E complex injections: literature review and report of two cases. <i>Immunologic Research</i> , 2017, 65, 285-292.	2.9	4
31	Update on antiphospholipid antibody syndrome. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2017, 63, 994-999.	0.7	22
32	Catastrophic antiphospholipid syndrome: A case with unusual findings revealed in autopsy and a brief literature update. <i>European Journal of Rheumatology</i> , 2017, 4, 281-283.	0.6	1
33	Definition and Epidemiology of Antiphospholipid Syndrome. , 2017, , 147-169.		1
34	The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. <i>Thrombosis and Haemostasis</i> , 2016, 115, 285-290.	3.4	66
35	Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. <i>Anais Brasileiros De Dermatologia</i> , 2016, 91, 137-139.	1.1	15
36	Direct oral anticoagulants in antiphospholipid syndrome. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 469-470.	0.7	1

#	ARTICLE	IF	CITATIONS
37	Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. <i>Autoimmunity Reviews</i> , 2016, 15, 955-963.	5.8	79
38	Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications. <i>Immunotherapy</i> , 2016, 8, 1427-1436.	2.0	10
39	Infliximab-induced autoantibodies: a multicenter study. <i>Clinical Rheumatology</i> , 2016, 35, 325-332.	2.2	26
40	The autoimmune diseases of the eyes. <i>Autoimmunity Reviews</i> , 2016, 15, 258-271.	5.8	33
41	Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. <i>Clinical Rheumatology</i> , 2016, 35, 801-805.	2.2	60
42	Anticoagula�o na gravidez. <i>Revista Hospital Universit�rio Pedro Ernesto</i> , 2015, 14, .	0.1	0
43	Understanding and Managing Pregnancy in Patients with Lupus. <i>Autoimmune Diseases</i> , 2015, 2015, 1-18.	0.6	50
44	Antiphospholipid Antibodies and Antiphospholipid Syndrome during Pregnancy: Diagnostic Concepts. <i>Frontiers in Immunology</i> , 2015, 6, 205.	4.8	25
45	The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. <i>Autoimmunity Reviews</i> , 2015, 14, 401-414.	5.8	194
46	The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis. <i>Lupus</i> , 2014, 23, 1299-1301.	1.6	19
47	Lepromatous Leprosy Mimicking Systemic Lupus Erythematosus. <i>HSS Journal</i> , 2014, 10, 286-291.	1.7	12
48	Reply. <i>Arthritis and Rheumatology</i> , 2014, 66, 480-480.	5.6	0
49	Cardiovascular Risk Factors in the Antiphospholipid Syndrome. <i>Journal of Immunology Research</i> , 2014, 2014, 1-6.	2.2	29
50	Antiphospholipid Syndrome and Antibodies. <i>Journal of Immunology Research</i> , 2014, 2014, 1-2.	2.2	1
51	Putting the value into biosimilar decision making. <i>Autoimmunity Reviews</i> , 2014, 13, 678-684.	5.8	23
52	Pregnancy Morbidity in Antiphospholipid Syndrome: What Is the Impact of Treatment?. <i>Current Rheumatology Reports</i> , 2014, 16, 403.	4.7	38
53	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
54	14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Autoimmunity Reviews</i> , 2014, 13, 685-696.	5.8	290

#	ARTICLE	IF	CITATIONS
55	Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 838-844.	0.9	123
56	Changes in anti-citrullinated protein antibody titers following treatment with infliximab for rheumatoid arthritis. <i>Israel Medical Association Journal</i> , 2014, 16, 17-9.	0.1	2
57	Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials. <i>Arthritis and Rheumatism</i> , 2013, 65, 2143-2153.	6.7	152
58	Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. <i>Lupus</i> , 2013, 22, 144-154.	1.6	106
59	Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 358-364.	0.7	7
60	Guidelines for the treatment of antiphospholipid syndrome. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 184-192.	0.7	9
61	Translation, cross-cultural adaptation and validation of the Brazilian version of the Nonarthritic Hip Score. <i>Sao Paulo Medical Journal</i> , 2013, 131, 244-251.	0.9	15
62	The Multiple Autoimmune Syndromes. A Clue for the Autoimmune Tautology. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 256-264.	6.5	64
63	Management of Obstetric Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2012, 14, 79-86.	4.7	30
64	APS ACTION no Brasil. <i>Revista Brasileira De Reumatologia</i> , 2012, 52, 813-814.	0.8	0
65	APS ACTION in Brazil. <i>Revista Brasileira De Reumatologia</i> , 2012, 52, 811-4.	0.8	0
66	Pregnancy may aggravate arterial hypertension in women with Takayasu arteritis. <i>Israel Medical Association Journal</i> , 2012, 14, 724-8.	0.1	12
67	Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2011, 377, 721-731.	13.7	1,629
68	Pneumonia intersticial associada Å esclerose sistÃmica: avaliaÃ£o da funÃ£o pulmonar no perÃodo de cinco anos. <i>Jornal Brasileiro De Pneumologia</i> , 2011, 37, 144-151.	0.7	15
69	Cutting-Edge Issues in Autoimmune Uveitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 41, 214-223.	6.5	15
70	Antiphospholipid Syndrome Clinical Research Task Force Report. <i>Lupus</i> , 2011, 20, 219-224.	1.6	36
71	Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. <i>Brazilian Journal of Medical and Biological Research</i> , 2010, 43, 403-408.	1.5	17
72	Obstetric antiphospholipid syndrome: still a challenge. <i>Lupus</i> , 2010, 19, 457-459.	1.6	23

#	ARTICLE	IF	CITATIONS
73	Estudo-piloto: c�lulas NK nas gestantes com LES. Revista Brasileira De Reumatologia, 2009, 49, 387-401.	0.8	1
74	Clotting, Immune System, and Venous Thrombosis in Lung Adenocarcinoma Patients: A Prospective Study. Cancer Investigation, 2009, 27, 989-997.	1.3	18
75	Lung adenocarcinoma and antiphospholipid antibodies. Autoimmunity Reviews, 2009, 8, 529-532.	5.8	12
76	Management of Patients With Rheumatoid Arthritis in Latin America. Journal of Clinical Rheumatology, 2009, 15, 203-210.	0.9	44
77	Infections and Autoimmunity: A Panorama. Clinical Reviews in Allergy and Immunology, 2008, 34, 283-299.	6.5	62
78	The impact of Arthritis & Rheumatism in Latin America. Arthritis and Rheumatism, 2008, 58, S145-S145.	6.7	0
79	Treatment of Raynaud's phenomenon. Autoimmunity Reviews, 2008, 8, 62-68.	5.8	37
80	Amputation of Digits or Limbs in Patients with Antiphospholipid Syndrome. Seminars in Arthritis and Rheumatism, 2008, 38, 124-131.	3.4	37
81	Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody�positive individuals. Arthritis and Rheumatism, 2007, 56, 2382-2391.	6.7	364
82	Lupus Anticoagulant Activity as a Thrombosis Risk Factor in Lung Adenocarcinoma Patients. Annals of the New York Academy of Sciences, 2007, 1107, 51-55.	3.8	6
83	Primary antiphospholipid nephropathy beginning during pregnancy. Rheumatology International, 2007, 27, 289-293.	3.0	6
84	Antiphospholipid Syndrome and Cognition. Clinical Reviews in Allergy and Immunology, 2007, 32, 188-191.	6.5	10
85	Correlation of Thrombosis and Prothrombotic Markers with Outcome in Lung Adenocarcinoma Patients: A Prospective Study.. Blood, 2007, 110, 3985-3985.	1.4	1
86	Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Research and Therapy, 2006, 8, 209.	3.5	469
87	Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study. American Journal of Medicine, 2006, 119, 255-266.	1.5	302
88	Contractile Cells and Fibrillin-1 Distribution is Disturbed in Terminal Villi of Placentae from Patients with Preeclampsia and Systemic Lupus Erythematosus. Placenta, 2006, 27, 234-243.	1.5	7
89	Latin American Autoimmunity and the Brazilian Anthropophagy. Clinical and Developmental Immunology, 2006, 13, 79-80.	3.3	0
90	Use of Anti-Rheumatic Drugs in Pregnancy. Handbook of Systemic Autoimmune Diseases, 2005, 4, 101-110.	0.1	1

#	ARTICLE	IF	CITATIONS
91	I Latin American Congress of Autoimmunity Galapagosâ€”September 15â€”18. Autoimmunity Reviews, 2004, 3, 76-87.	5.8	0
92	An adapted ELISA method for differentiating pathogenic from nonpathogenic aPL by a beta 2 glycoprotein I dependency anticardiolipin assay. Thrombosis Research, 2004, 114, 573-577.	1.7	25
93	Treatment of pregnant patients with antiphospholipid syndrome. Lupus, 2003, 12, 524-529.	1.6	120
94	The catastrophic antiphospholipid syndrome--Asherson's syndrome. Annales De MÃ©decine Interne, 2003, 154, 195-6.	0.2	18
95	Prevention of thrombosis during pregnancy. Israel Medical Association Journal, 2002, 4, 794-7.	0.1	6
96	Mechanisms of Pregnancy Loss in Antiphospholipid Syndrome. Clinical Obstetrics and Gynecology, 2001, 44, 11-19.	1.1	51
97	Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus, 2001, 10, 401-404.	1.6	364
98	Catastrophic Antiphospholipid Syndrome: Clinical and Laboratory Features of 50 Patients. Medicine (United States), 1998, 77, 195-207.	1.0	478
99	Clinical Manifestations of the aPL Syndrome. Lupus, 1996, 5, 393-397.	1.6	18
100	Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein. Journal of Clinical Immunology, 1992, 12, 27-35.	3.8	76
101	Fatty acid chain is a critical epitope for antiphospholipid antibody. Journal of Clinical Immunology, 1990, 10, 141-145.	3.8	30
102	Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds. Journal of Clinical Immunology, 1990, 10, 200-203.	3.8	24
103	Characteristics of high-titer igg antiphospholipid antibody in systemic lupus erythematosus patients with and without fetal death. Arthritis and Rheumatism, 1990, 33, 501-504.	6.7	51
104	Characteristics of IgG antiphospholipid antibodies in patients with systemic lupus erythematosus and syphilis. Journal of Rheumatology, 1990, 17, 1036-41.	2.0	37
105	IgG but not IgM anti-phospholipid antibody binding is temperature dependent. Journal of Clinical Immunology, 1988, 8, 188-192.	3.8	29